International Assets Investment Management LLC Buys 6,886 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

International Assets Investment Management LLC lifted its position in Privia Health Group, Inc. (NASDAQ:PRVA) by 2,721.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,139 shares of the company’s stock after buying an additional 6,886 shares during the quarter. International Assets Investment Management LLC’s holdings in Privia Health Group were worth $164,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PRVA. Loomis Sayles & Co. L P grew its position in shares of Privia Health Group by 1.2% in the 3rd quarter. Loomis Sayles & Co. L P now owns 623,870 shares of the company’s stock valued at $14,349,000 after acquiring an additional 7,577 shares during the period. Walleye Capital LLC acquired a new position in Privia Health Group during the third quarter worth approximately $1,394,000. Riverbridge Partners LLC raised its stake in Privia Health Group by 8.7% in the fourth quarter. Riverbridge Partners LLC now owns 4,342,385 shares of the company’s stock valued at $100,005,000 after buying an additional 348,852 shares during the period. Vanguard Group Inc. lifted its position in shares of Privia Health Group by 0.5% in the third quarter. Vanguard Group Inc. now owns 11,003,989 shares of the company’s stock valued at $253,092,000 after buying an additional 51,317 shares during the last quarter. Finally, Great Lakes Advisors LLC bought a new position in shares of Privia Health Group during the 3rd quarter worth approximately $3,534,000. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Privia Health Group

In related news, CFO David Mountcastle sold 3,933 shares of Privia Health Group stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total value of $69,889.41. Following the transaction, the chief financial officer now directly owns 262,279 shares of the company’s stock, valued at $4,660,697.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.20% of the stock is currently owned by insiders.

Privia Health Group Price Performance

Privia Health Group stock opened at $18.26 on Monday. The stock’s fifty day moving average price is $19.81 and its two-hundred day moving average price is $21.22. The firm has a market cap of $2.17 billion, a PE ratio of 96.11, a price-to-earnings-growth ratio of 2.50 and a beta of 0.81. Privia Health Group, Inc. has a one year low of $17.54 and a one year high of $30.15.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The company had revenue of $440.80 million during the quarter, compared to analyst estimates of $425.81 million. Privia Health Group had a net margin of 1.39% and a return on equity of 3.97%. The firm’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period last year, the firm earned $0.14 EPS. Sell-side analysts expect that Privia Health Group, Inc. will post 0.26 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PRVA has been the topic of a number of research analyst reports. Bank of America cut Privia Health Group from a “buy” rating to a “neutral” rating and dropped their price target for the company from $27.00 to $21.00 in a research note on Thursday, February 22nd. Barclays assumed coverage on shares of Privia Health Group in a research note on Wednesday, March 6th. They issued an “equal weight” rating and a $22.00 price target on the stock. Jefferies Financial Group assumed coverage on shares of Privia Health Group in a research report on Monday, February 26th. They set a “buy” rating and a $25.00 price objective for the company. UBS Group decreased their target price on Privia Health Group from $31.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, March 1st. Finally, Citigroup initiated coverage on Privia Health Group in a research note on Monday, April 22nd. They issued a “buy” rating and a $25.00 price target for the company. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.92.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.